2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma

2018 ◽  
Vol 101 ◽  
pp. 181-190 ◽  
Author(s):  
Kyoichi Kaira ◽  
Kimihiro Shimizu ◽  
Shinsuke Kitahara ◽  
Toshiki Yajima ◽  
Jun Atsumi ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Glucose Uptake ◽  
Pulmonary Adenocarcinoma ◽  
Emission Tomography ◽  
Programmed Death Ligand 1 ◽  
Positron Emission ◽  
Programmed Death

scholarly journals P04.04 Programmed death-ligand 1 positron emission tomography imaging during neoadjuvant (chemo)radiotherapy in esophageal and rectal cancer (PETNEC): a prospective non-randomized open-label single-center pilot study

2021 ◽  
Vol 9 (Suppl 1) ◽  
pp. A17.3-A18
Author(s):  
J Laengle ◽  
D Tamandl ◽  
R Schmid ◽  
J Widder ◽  
M Bergmann ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Rectal Cancer ◽  
Pilot Study ◽  
Emission Tomography ◽  
Single Center ◽  
Open Label ◽  
Programmed Death Ligand 1 ◽  
Positron Emission ◽  
Programmed Death ◽  
Imaging Approach

BackgroundImmune checkpoint inhibitors (ICI), such as atezolizumab (anti-programmed death-ligand 1; PD-L1), have been proven to be an effective strategy in solid cancers. However, the overall response rate to ICI is currently limited to an intrinsically responsive tumor immune microenvironment (TIME) or depended on an appropriate foregone immune stimulus, such as radiotherapy. The concept of combining radiotherapy with ICI is currently investigated in a variety of solid cancers. However, little data is known on the expression dynamics of immune checkpoint ligands, such as PD-L1, during neoadjuvant chemoradiotherapy (CRT) or short-course preoperative radiotherapy (SCPRT) in human solid malignancies.Materials and MethodsThis is a prospective non-randomized open-label single-center investigator-initiated pilot study (NCT no. NCT04564482). Patients with either rectal cancer (RC), oesophageal adenocarcinoma (EAC), gastroesophageal junction (GEJ) cancer or oesophageal squamous cell carcinoma (ESCC), whom are assigned by the routine multidisciplinary tumor board (MDT) to receive a standard neoadjuvant CRT/SCPRT, will be enrolled. Standard neoadjuvant regimens include CRT (50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO) or SCPRT (25 Gy in 5 Gy fractions over 5 working days) for RC patients and CRT according to the CROSS protocol (41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W) for patients with EAC, ESCC or GEJ cancer. Patients will receive a PD-L1 (89Zr-atezolizumab) positron emission tomography (PET) CT (for EAC, ESCC or GEJ cancers) or MRI (for RC) bevor (day 0) and during neoadjuvant treatment (day 10-14).ResultsThe primary endpoint of this pilot study is the none-invasive assessment of PD-L1 expression dynamics during neoadjuvant CRT/SCPRT by a PD-L1 PET imaging approach. Secondary objectives are the correlation between PD-L1 PET expression dynamics and radiographic as well as pathological therapy response.ConclusionsThis is the first in human study, which assesses PD-L1 expression dynamics during different neoadjuvant radiotherapeutic regimens. A detailed understanding of the impact of radiotherapy on PD-L1 expression, monitored by an none-invasive PET imaging approach, allows the application of radiotherapy as part of a novel immunotherapeutic concept.Disclosure InformationJ. Laengle: None. D. Tamandl: None. R. Schmid: None. J. Widder: None. M. Bergmann: None. A. Haug: None.

Evaluation of individual skeletal muscle activity by glucose uptake during pedaling exercise at different workloads using positron emission tomography

2009 ◽  
Vol 107 (2) ◽  
pp. 599-604 ◽  
Author(s):  
Yuichi Gondoh ◽  
Manabu Tashiro ◽  
Masatoshi Itoh ◽  
Mohammad M. Masud ◽  
Hiroomi Sensui ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Positron Emission Tomography ◽  
Glucose Uptake ◽  
Muscle Activity ◽  
Rectus Femoris ◽  
Emission Tomography ◽  
Whole Body ◽  
Control Subjects ◽  
Positron Emission ◽  
Iliacus Muscle

Skeletal muscle glucose uptake closely reflects muscle activity at exercise intensity levels <55% of maximal oxygen consumption (V̇o2max). Our purpose was to evaluate individual skeletal muscle activity from glucose uptake in humans during pedaling exercise at different workloads by using [18F]fluorodeoxyglucose (FDG) and positron emission tomography (PET). Twenty healthy male subjects were divided into two groups (7 exercise subjects and 13 control subjects). Exercise subjects were studied during 35 min of pedaling exercise at 40 and 55% V̇o2max exercise intensities. FDG was injected 10 min after the start of exercise or after 20 min of rest. PET scanning of the whole body was conducted after completion of the exercise or rest period. In exercise subjects, mean FDG uptake [standardized uptake ratio (SUR)] of the iliacus muscle and muscles of the anterior part of the thigh was significantly greater than uptake in muscles of control subjects. At 55% V̇o2max exercise, SURs of the iliacus muscle and thigh muscles, except for the rectus femoris, increased significantly compared with SURs at 40% V̇o2max exercise. Our results are the first to clarify that the iliacus muscle, as well as the muscles of the anterior thigh, is the prime muscle used during pedaling exercise. In addition, the iliacus muscle and all muscles in the thigh, except for the rectus femoris, contribute when the workload of the pedaling exercise increases from 40 to 55% V̇o2max.

scholarly journals Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial

2021 ◽  
Author(s):  
Martina Broecker-Preuss ◽  
Nina Becher-Boveleth ◽  
Stefan P. Müller ◽  
Andreas Hüttmann ◽  
Christine Hanoun ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Glucose Uptake ◽  
Statistical Significance ◽  
B Cell Lymphoma ◽  
Tumour Volume ◽  
Minor Allele ◽  
Emission Tomography ◽  
Time To Progression ◽  
Positron Emission ◽  
Pet Ct

Abstract Background [18F]Fluoro-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging procedure in diffuse large B-cell lymphoma (DLBCL). Disease presentation, FDG-PET/CT performance, and outcome may be influenced by germline single nucleotide polymorphisms (SNP) in genes regulating glucose uptake. Methods Clinical variables, FDG-PET findings, and outcome were analysed in relation to SNPs in 342 DLBCL patients participating in the ‘Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas’ (PETAL) trial. Genes analysed included SLC2A1 (SNPs rs1385129, referred to as HaeIII; rs710218, HpyCH4V; rs841853, XbaI), VEGFA (rs3025039), HIF1A (rs11549465, P582S; rs11549467, A588T), and APEX1 (rs1130409, D148E). Statistical significance was assumed at p ≤ 0.05. Results The SLC2A1 HaeIII and HpyCH4V SNPs were tightly linked and statistically significantly associated with baseline maximum standardized uptake value (SUVmax) and Ann Arbor stage, with slightly lower SUVmax (HaeIII, median 18.9, interquartile range [IQR] 11.5–26.6, versus 21.6, IQR 14.4–29.7; p = 0.019) and more frequent stage IV disease (HaeIII, 44.5% versus 30.8%; p = 0.011) in minor allele carriers. As previously reported for lung cancer, the association was dependent upon the coexistent APEX1 D148E genotype. The HIF1A A588T SNP was associated with total metabolic tumour volume (TMTV) and time-to-progression, with significantly lower TMTV (median 16 cm3, IQR 7–210, versus 146 cm3, IQR 34–510; p = 0.034) and longer time-to-progression in minor allele carriers (log-rank p = 0.094). Time-to-progression was also associated with the SLC2A1 XbaI and APEX1 D148E SNPs, with shorter time-to-progression in homozygous and heterozygous SLC2A1 XbaI (HR 1.456; CI 0.930–2.280; p = 0.099) and homozygous APEX1 D148E minor allele carriers (HR 1.6; CI 1.005–2.545; p = 0.046). In multivariable analyses including SNPs, International Prognostic Index factors, sex, and B symptoms, HIF1A A588T, SLC2A1 XbaI, and APEX1 D148E retained statistical significance for time-to-progression, and SLC2A1 XbaI was also significantly associated with overall survival. Conclusions Common SNPs in genes regulating glucose uptake may impact SUVmax, tumour distribution, tumour volume, and outcome in DLBCL. The effects on SUVmax are of low magnitude and appear clinically negligible. The results are consistent with findings in other types of cancer. They need to be confirmed in an independent DLBCL population of sufficient size. Trial registration Trial registration: ClinicalTrials.gov NCT00554164; EudraCT 2006-001641-33. Registration date November 5, 2007, https://www.clinicaltrials.gov/ct2/show/NCT00554164

Sign in / Sign up

Export Citation Format

Share Document